Grants per year
Personal profile
Research Interests
Mood disorders, Psychopharmacology
Certifications and Licenses
| Psychiatry |
Training Experience
| 1991 | Internship, Saint Luke's Hospital |
| 1994 | Residency, New York State Psychiatric Institute |
| 1996 | Fellowship, New York State Psychiatric Institute |
Education/Academic qualification
MD, University of Illinois - Chicago
… → 1990
Research interests
- Anxiety Disorders
- Cognitive Neuroscience
- Depression
- Mental Health
- Mood Disorders
- Neurology
- Neuropsychology
- Psychiatry
Fingerprint Dive into the research topics where Pedro L Dago is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 5 Similar Profiles
Bipolar Disorder
Medicine & Life Sciences
Treatment-Resistant Depressive Disorder
Medicine & Life Sciences
Piperazines
Medicine & Life Sciences
Psychopharmacology
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Psychomotor Agitation
Medicine & Life Sciences
Mood Disorders
Medicine & Life Sciences
Antidepressive Agents
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2004 2012
- 5 Finished
Prot# BAP01346: Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy
Dago, P. L., Laumann, A. E., Martini, M. C. & West, D. P.
Covance Periapproval Services, Inc., Basilea Pharmaceutica International Ltd.
5/26/09 → 5/26/12
Project: Research project
Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD)
3/1/06 → 1/10/08
Project: Research project
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Cambridge Health Alliance, Janssen Pharmaceutica, Inc.
10/25/04 → 11/1/11
Project: Research project
Double-Blind, Placebo-Controlled Trial Depakote-ER for Depressive and Anxiety Symptoms in Non-Refractory Bipolar Depression
Cambridge Health Alliance, Abbott Laboratories
6/25/04 → 12/31/08
Project: Research project
Research Output 1995 2016
21
Citations
(Scopus)
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia
Keefe, R. S. E., Haig, G. M., Marder, S. R., Harvey, P. D., Dunayevich, E., Medalia, A., Davidson, M., Lombardo, I., Bowie, C. R., Buchanan, R. W., Bugarski-Kirola, D., Carpenter, W. T., Csernansky, J. G., Dago, P. L., Durand, D. M., Frese, F. J., Goff, D. C., Gold, J. M., Hooker, C. I., Kopelowicz, A. & 5 others, , Jan 1 2016, In : Schizophrenia bulletin. 42, 1, p. 19-33 15 p.Research output: Contribution to journal › Article
Schizophrenia
Consensus
Clinical Trials
Therapeutics
Reproducibility of Results
Introduction: Treatment along the life cycle
Dago, P., Sep 1 2013, In : Psychiatric Times. 30, 9Research output: Contribution to journal › Comment/debate
Life Cycle Stages
Factors that impact choice of antidepressant treatment in medically complex patients.
Dago, P. L., Jan 1 2009, In : CNS Spectrums. 14, 12 Suppl 12, p. 20-27 8 p.Research output: Contribution to journal › Article
Antidepressive Agents
Major Depressive Disorder
Pharmacokinetics
Therapeutics
Serotonin and Noradrenaline Reuptake Inhibitors
An association of intrusive, repetitive phrase with lomotrigine treatment in bipolar II disorder
Kemp, D. E., Gilmer, W. S., Fleck, J. & Dago, P. L., Feb 1 2007, In : CNS Spectrums. 12, 2, p. 106-111 6 p.Research output: Contribution to journal › Review article
Bipolar Disorder
Therapeutics
Vulnerable Populations
Mood Disorders
lamotrigine
12
Citations
(Scopus)
Aripiprazole augmentation for treatment-resistant bipolar depression: Sustained remission after 36 months [3]
Kemp, D. E., Dago, P. L., Straus, J. L., Fleck, J., Karaffa, M. & Gilmer, W. S., Jun 1 2007, In : Journal of Clinical Psychopharmacology. 27, 3, p. 304-305 2 p.Research output: Contribution to journal › Letter
Piperazines
Treatment-Resistant Depressive Disorder
Quinolones
Combination Drug Therapy
Bipolar Disorder